drugset / Trial / NCT02946437

Sevoflurane in Subarachnoidal Haemorrhage

NCT02946437

Phase 2 Withdrawn University of Zurich
RandomizedParallel-groupOpen-labelTreatment

Summary

Feasibility and safety of short term application of sevoflurane in patients with SAH treated with aneurysm coiling or clipping in the setting of a neurointensive care unit.

Timeline

Start
2015-11-01
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midazolam Small molecule 0.03 mg/kg Intravenous
Comparator Midazolam Small molecule 0.2 mg/kg Intravenous
Comparator Propofol Small molecule 0.3 mg/kg Intravenous
Comparator Propofol Small molecule 4 mg/kg Intravenous
Subject Sevoflurane Other / unclassified 0.5 % Inhaled
Subject Sevoflurane Other / unclassified 1.5 % Inhaled